Fig. 1From: BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studiesKey milestones in the development of BTK inhibitors, with approved indications. XLA X-linked agammaglobulinemia; GVHD graft-versus-host disease; R/R relapsed and refractory; TN treatment-naïveBack to article page